Vesting

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, June 4, 2021

The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Vesting of the option award is subject to continued service with AVROBIO by the employee through the applicable vesting dates.
  • AVROBIO is powered by our industry leading plato gene therapy platform, our foundation designed to deliver gene therapy worldwide.
  • AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference

Retrieved on: 
Wednesday, June 2, 2021

San Diego, California--(Newsfile Corp. - June 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the "Psychedelics in Psychiatry and Beyond" conference sponsored by H.C. Wainwright & Co.

Key Points: 
  • San Diego, California--(Newsfile Corp. - June 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the "Psychedelics in Psychiatry and Beyond" conference sponsored by H.C. Wainwright & Co.
  • The term and vesting periods of the New Options are identical to the term and vesting periods of the Cancelled Options.
  • Tryp Therapeutics is a pharmaceutical company focused on developing compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.
  • These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully.

Lundin Mining Announces Updated Share Capital and Voting Rights

Retrieved on: 
Monday, May 31, 2021

TORONTO, May 31, 2021 /PRNewswire/ -- (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation ("Lundin Mining" or the "Company") reports the following updated share capital and voting rights, in accordance with the Swedish Financial Instruments Trading Act:

Key Points: 
  • TORONTO, May 31, 2021 /PRNewswire/ -- (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation ("Lundin Mining" or the "Company") reports the following updated share capital and voting rights, in accordance with the Swedish Financial Instruments Trading Act:
    As a result of the exercise of employee stock options or the vesting of employee share units from May 1,2021 to date, the number of issued and outstanding shares of the Company has increased by 702,869 to 739,064,880common shares with voting rights as at May 31, 2021.
  • Lundin Mining is a diversified Canadian base metals mining company with operations in Brazil, Chile, Portugal, Sweden and the United States of America, primarily producing copper, zinc, gold and nickel.
  • The information in this release is subject to the disclosure requirements of Lundin Mining under the Swedish Financial Instruments Trading Act.
  • The information was submitted for publication, through the agency of the contact persons set out below on May 31, 2021 at 17:00 Eastern Time.

Kaizen Discovery Grants Stock Options

Retrieved on: 
Thursday, May 20, 2021

b'Vancouver, British Columbia--(Newsfile Corp. - May 20, 2021) - Kaizen Discovery Inc. (TSXV: KZD) (otherwise "Kaizen" or "the Company") announces today that, pursuant to its Stock Option Plan, it has granted incentive stock options to its independent directors to purchase up to an aggregate of 428,570 common shares in the capital stock of the company.\nThe options are exercisable at a price of $0.07 per share and will vest 33 1/3% six (6) months after the date of the grant, with an additional 33 1/3% vesting twelve (12) months after the date of grant and the remaining 33 1/3% vesting two (2) years after the date of grant.

Key Points: 
  • b'Vancouver, British Columbia--(Newsfile Corp. - May 20, 2021) - Kaizen Discovery Inc. (TSXV: KZD) (otherwise "Kaizen" or "the Company") announces today that, pursuant to its Stock Option Plan, it has granted incentive stock options to its independent directors to purchase up to an aggregate of 428,570 common shares in the capital stock of the company.\nThe options are exercisable at a price of $0.07 per share and will vest 33 1/3% six (6) months after the date of the grant, with an additional 33 1/3% vesting twelve (12) months after the date of grant and the remaining 33 1/3% vesting two (2) years after the date of grant.
  • The options expire on May 19, 2026.\nKaizen is a Canadian mineral exploration and development company with exploration projects in Peru and Canada.
  • More information on Kaizen is available at www.kaizendiscovery.com\n'

LifeMD™ Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, May 17, 2021

The award was granted outside of the Company\xe2\x80\x99s 2020 Equity and Incentive Plan (but consistent with its terms) and approved on May 17, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).\nThe employee received options to purchase an aggregate of 75,000 shares of LifeMD, Inc. common stock.

Key Points: 
  • The award was granted outside of the Company\xe2\x80\x99s 2020 Equity and Incentive Plan (but consistent with its terms) and approved on May 17, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).\nThe employee received options to purchase an aggregate of 75,000 shares of LifeMD, Inc. common stock.
  • The options have an exercise price of $7.73, which is equal to the closing price of LifeMD common stock on May 17, 2021, the grant date of the award.
  • The options will vest in three equal installments annually over a 3-year period that commences on the date of grant, subject to the employee\xe2\x80\x99s continued employment with LifeMD on such vesting dates.
  • All forward-looking statements attributable to LifeMD, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.\n'

The Real Brokerage Inc. Opens in New Hampshire; Announces Normal Course Issuer Bid

Retrieved on: 
Monday, May 17, 2021

Under the Plan, vested RSUs are redeemable for Shares, a cash payment equivalent to the value of a Share or a combination of cash or Shares.

Key Points: 
  • Under the Plan, vested RSUs are redeemable for Shares, a cash payment equivalent to the value of a Share or a combination of cash or Shares.
  • The RSU Plan provides that Shares available to satisfy such redemption will be acquired on the market.
  • Through the trustee, RBC Capital Markets ("RBCCM") has been engaged to undertake purchases under the NCIB for the purposes of the RSU Plan.
  • Real creates financial opportunities for agents through better commission splits, best-in-class technology, revenue sharing and equity incentives.\n'

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 14, 2021

These equity awards were granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employee\xe2\x80\x99s acceptance of employment with the Company.\nThe options have an exercise price of $1.62 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date.

Key Points: 
  • These equity awards were granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employee\xe2\x80\x99s acceptance of employment with the Company.\nThe options have an exercise price of $1.62 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date.
  • The RSUs vest in full on the two-year anniversary of May 3, 2021, subject to the employee\xe2\x80\x99s continued employment on such vesting date.\nSavara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
  • Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
  • Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

OROCO GRANTS INCENTIVE STOCK OPTIONS

Retrieved on: 
Tuesday, May 11, 2021

b'Vancouver, Canada, May 11, 2021 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO) (\xe2\x80\x9cOroco\xe2\x80\x9d or \xe2\x80\x9cthe Company\xe2\x80\x9d) announces the grant of incentive stock options to its directors, officers, management personnel and consultants to acquire an aggregate of 4,425,000 common shares in the capital of the Company at an exercise price of $3.15 per share (the \xe2\x80\x9cOptions\xe2\x80\x9d).\nThe Options are exercisable for a three-year term, expiring on May 10, 2024, with 20% vesting immediately and a further 20% vesting every 6 months over the next two years.\nThe Options were granted in accordance with the Company\xe2\x80\x99s 10% rolling incentive stock option plan.

Key Points: 
  • b'Vancouver, Canada, May 11, 2021 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO) (\xe2\x80\x9cOroco\xe2\x80\x9d or \xe2\x80\x9cthe Company\xe2\x80\x9d) announces the grant of incentive stock options to its directors, officers, management personnel and consultants to acquire an aggregate of 4,425,000 common shares in the capital of the Company at an exercise price of $3.15 per share (the \xe2\x80\x9cOptions\xe2\x80\x9d).\nThe Options are exercisable for a three-year term, expiring on May 10, 2024, with 20% vesting immediately and a further 20% vesting every 6 months over the next two years.\nThe Options were granted in accordance with the Company\xe2\x80\x99s 10% rolling incentive stock option plan.
  • During that time, the property was tested by over 100 diamond and reverse circulation drill holes, totaling approximately 30,000 meters.
  • \xc2\xa0All statements, other than statements of historical fact included herein, including without limitation, statements relating to future events or achievements of the Company, are forward-looking statements.
  • \xc2\xa0Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these matters.\xc2\xa0 Oroco does not assume any obligation to update the forward-looking statements should they change, except as required by law.\n'

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 7, 2021

The options have an exercise price per share equal to $27.04, which was the closing trading price on May 3, 2021, the date of the grants.

Key Points: 
  • The options have an exercise price per share equal to $27.04, which was the closing trading price on May 3, 2021, the date of the grants.
  • The inducement awards will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the date of grants and 1/48th of the underlying shares vesting monthly thereafter over 36 months.
  • Prothena\xe2\x80\x99s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer\xe2\x80\x99s disease, Parkinson\xe2\x80\x99s disease and a number of other neurodegenerative diseases.
  • For more information, please visit the Company\xe2\x80\x99s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.\n'

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 7, 2021

b'BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo\xe2\x80\x99s common stock.

Key Points: 
  • b'BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo\xe2\x80\x99s common stock.
  • The stock options are exercisable at a price of $30.37 per share, the closing price of Albireo\xe2\x80\x99s common stock on May 4, 2021, the grant date, and were granted as inducements material to the employee\xe2\x80\x99s acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and vests over a four-year period, subject to the employee\xe2\x80\x99s continued service with Albireo through the applicable vesting dates.
  • The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.